Approximately 75% of all disease-relevant human proteins, including those involved in
intracellular protein–protein interactions (PPIs), are undruggable with the current drug …

A large proportion of protein–protein interactions (PPIs) occur between a short peptide and a
globular protein domain; the peptides involved in surface interactions play important roles …

Peptides are a growing therapeutic class due to their unique spatial characteristics that can
target traditionally “undruggable” protein–protein interactions and surfaces. Despite their …

In the past decade, multicomponent reactions have experienced a renaissance as powerful
peptide macrocyclization tools enabling the rapid creation of skeletal complexity and …

Extensive immune evasion of SARS-CoV-2 rendered therapeutic antibodies ineffective in
the COVID-19 pandemic. Propagating SARS-CoV-2 variants are characterised by immune …

Macrocycles have long been recognized as useful chemical entities for medicine, with
naturally occurring and synthetic macrocycles clinically approved for use as prescription …

Protein–protein interactions (PPIs) are implicated in the majority of cellular processes by
enabling and regulating the function of individual proteins. Thus, PPIs represent high-value …

Easy access to a wide range of structurally diverse stapled peptides is crucial for the
development of inhibitors of protein‐protein interactions. Herein, we report bis‐functional …

ABSTRACT SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) as the
primary receptor to enter host cells and initiate the infection. The critical binding region of …

While the global market for peptide/protein-based therapeutics is witnessing significant
growth, the development of peptide drugs remains challenging due to their low oral …